Shots:
- The CDSCO has granted a EUA for Roche’s casirivimab and imdevimab to treat COVID-19 in India. The approval of the Ab cocktail was based on the data that has been filed for the EUA in the US and the CHMP’s opinion in the EU
- Roche will import the globally manufactured product batches to India and is collaborated with Cipla for pan-India distribution. At a global level, Roche and Regeneron are collaborating to jointly address the increasing demand
- Earlier, Roche has reported the global P-III trial of Abs vs PBO in 4,567 high-risk non-hospitalized COVID-19 patients and showed a 70% reduction in the risk of hospitalization or death and also shortened the duration of symptoms @4days
Click here to read full press release/ article | Ref: Cipla | Image: Cipla
The post Roche’s Ab Cocktail (Casirivimab and Imdevimab) Receives EUA to Treat COVID-19 in India first appeared on PharmaShots.
